PURPOSE: A composition containing an effective amount of an actin inhibitor or a derivative thereof and specifically acting on cancer by p53 or p21 gene mutation without affecting normal cells is provided. Therefore, it has cell apoptosis effect by inducing continuous DNA synthesis and mitosis while inhibiting cytokinesis. CONSTITUTION: A pharmaceutical composition for the treatment of cancer by p53 or p21 gene mutation contains an actin inhibitor or a derivative thereof as an active component and a pharmaceutically effective amount of a pharmaceutically acceptable carrier. The actin inhibitor is one or more selected from cytochalasin D, latrunculin, jaspamide, swinholide A, misakinolide A and halichondramide.
展开▼
